VIRVir Biotechnology Inc
VIR
Vir Biotechnology Inc6,329
Mkt Cap
$790.23MVolume
2,479.0052W High
$14.4552W Low
$4.16PE Ratio
-1.57VIR Fundamentals
Price
$5.68Prev Close
$5.56Open
$5.5650D MA
$5.62Beta
1.50Avg. Volume
1.5MEPS (Annual)
-$3.83P/B
0.99Rev/Employee
$181,875.00Vir Biotechnology (NASDAQ:VIR) CFO Sells $37,802.44 in Stock
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CFO Jason O'byrne sold 6,799 shares of Vir Biotechnology stock in a transaction on Monday, November 17th. The stock was sold at an average price...
MarketBeat·5d ago
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare...
Business Wire·5d ago
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven analysts that are presently covering the stock, MarketBeat...
MarketBeat·14d ago
Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown
Phase 2 trial showed 66% of patients achieved undetectable hepatitis delta virus RNA with Vir’s tobevibart-elebsiran combo, with no serious safety issues reported.
Vir Biotechnology Announces AASLD The Liver Meeting Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Companys Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that participants...
Business Wire·14d ago
Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells 2,385 Shares of Stock
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) EVP Verneuil Vanina De sold 2,385 shares of the company's stock in a transaction dated Wednesday, November 5th. The shares were sold at an...
MarketBeat·16d ago
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday...
Business Wire·17d ago
Vir Biotechnology (NASDAQ:VIR) Releases Quarterly Earnings Results, Misses Expectations By $0.47 EPS
Vir Biotechnology (NASDAQ:VIR - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of...
MarketBeat·18d ago
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -67.14% and -96.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·19d ago
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View
GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.
Zacks·26d ago